Articles

SCOPE X 2026: Key Insights and Coverage

SCOPE X 2026 is set to be a pivotal event for B2B readers in the pharma sector. This article covers key insights, company watchlists, and essential data readouts.

Virginia Governor Vetoes Legislation on Prescription Drug Costs

The Virginia governor has vetoed a bill aimed at creating a panel to lower prescription drug costs. This decision raises questions about future drug pricing strategies in the state.

Britain's Tobacco Regulation: Lessons from Massachusetts

This article examines Britain's adoption of Massachusetts tobacco regulations and the potential implications for the pharmaceutical sector.

Palvella's Nasdaq Uplisting: Implications for Rare Disease Development

Palvella Therapeutics has achieved a significant milestone by earning a spot on a stricter Nasdaq tier, signaling growth potential in the rare disease sector. This article analyzes the implications for investors and pharma teams.

FDA's Unreleased Covid Vaccine Deaths Report: What You Need to Know

This article delves into the recently published report on Covid vaccine deaths by the FDA, highlighting its implications for the pharmaceutical industry.

Supreme Court Setback for Pharma and TrumpRx Expansion Insights

This article discusses the recent Supreme Court setback for the pharmaceutical industry and the expansion of TrumpRx, providing key insights for B2B readers.

The Financial Implications of Spine Surgery Under the No Surprises Act

This article examines the stark contrast in spine surgery costs due to the No Surprises Act arbitration, highlighting implications for the pharmaceutical industry.

Canadian Medical Societies' Conflict-of-Interest Policies Under Scrutiny

A recent study highlights the inadequacy of conflict-of-interest policies in Canadian medical societies, raising concerns for the pharmaceutical industry. This article explores the implications for pharma teams and stakeholders.

Impact of 600 New Generic Meds on Pharma Purchasing

The White House has added 600 generic medications to the TrumpRx purchasing portal, signaling significant changes in the pharmaceutical landscape. This article explores the implications for pharma teams and investors.

Novartis Ends Contract with Porton: Legal Implications and Market Impact

Novartis has terminated its contract with Chinese CDMO Porton, raising significant legal and market implications. This article explores the fallout and what it means for the pharmaceutical industry.

Supreme Court Declines to Hear Drugmakers' IRA Cases

The Supreme Court's decision not to hear drugmakers' IRA cases raises significant questions for the pharmaceutical industry. This article explores the implications for business and investment strategies.

Driving Impact: The Role of Medical Affairs in Pharmaceutical Launches

This article delves into the critical role of medical affairs in pharmaceutical launches, highlighting its impact on business strategies and market success.

The Latest on Ebola: Travel Ban and Old Vaccine Insights

This article delves into the recent travel ban related to Ebola and the implications of using an old vaccine, providing insights for pharmaceutical professionals.

Navigating Ghost Approval in Heart Transplant Medications

This article discusses the challenges faced by heart transplant recipients regarding medication approvals and the implications for the pharmaceutical industry.

Maryland Caps Ozempic Prices: Implications for Pharma

Maryland's affordability board has placed a price cap on Ozempic, raising questions about its impact on the pharmaceutical landscape. This article explores the implications for industry stakeholders.

The Alarming Impact of Alcohol Consumption During Pregnancy

A recent STAT+ report reveals that 1 in 8 women consume alcohol during pregnancy, raising concerns among experts about potential consequences for fetal health and the pharmaceutical sector.

Full-Life Technologies Secures $150M; Quince's New Pulmonary Drug Strategy

Full-Life Technologies has successfully raised $150 million to advance its initiatives, while Quince is rebooting its strategy with a new pulmonary drug. This article explores the implications for the pharmaceutical industry.

Nourish Secures $100M for Virtual Nutrition Care Expansion

Nourish has successfully raised $100 million to expand its virtual nutrition care services. This significant investment highlights the growing importance of nutrition in healthcare.

Relay Drug Shows Early Promise Against Rare Blood Vessel Diseases

Relay's drug demonstrates early efficacy in treating rare blood vessel diseases, signaling potential market opportunities and investment implications.

FDA Approves AstraZeneca’s Baxdrostat for Hypertension

The FDA has approved AstraZeneca's baxdrostat for treating hypertension, marking a significant milestone in hypertension management. This article explores the implications for pharmaceutical stakeholders.